IRD Q3 2024 Earnings — Opus Genetics, Inc. Revenue & Financial Results | Market Cap Arena

IRDOpus Genetics, Inc.

$349M

Q3 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$4M-67.6% YoY

Gross Profit

$4M100.0% margin

Operating Income

-$8M-207.1% margin

Net Income

-$8M-194.6% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

+247.8%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$5M

Stock-Based Comp.

$776,000

Balance Sheet

Total Assets

$40M

Total Liabilities

$6M

Stockholders' Equity

$34M

Cash & Equivalents

$37M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4M	$12M	-67.6%
Gross Profit	$4M	$12M	-67.6%
Operating Income	-$8M	$6M	-225.4%
Net Income	-$8M	$6M	-235.3%